Cost-effectiveness of CRC screening after age 75 varies by sex, comorbidities, history
Cost-effectiveness and optimal stopping ages for colorectal cancer screening after age 75 years appear to be associated with an individual’s age, sex, comorbidity status and screening history, according to results of an economic evaluation. “The burden and benefits of CRC screening depend on the individual’s overall life expectancy and CRC risk,” Matthias Harlass, MS, of